carbidopa/levodopa / Generic mfg. - LARVOL DELTA

Resolution of Levodopa/Dopa-Decarboxylase Inhibitor-Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature. (PubMed, Mov Disord Clin Pract) - "In PwP presenting with LDDCI-associated MC, CSFLI represents an effective alternative that maintains dopaminergic efficacy while bypassing the gastrointestinal tract. Early recognition and timely switching to parenteral levodopa formulations may prevent prolonged symptoms and complications of MC in PwP. Microscopic colitis, a rare adverse effect of LDDCI therapy, may resolve completely with CSFLI."

Journal • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Movement Disorders • Parkinson's Disease

Non-ICANS Neurologic Toxicity Following Chimeric Antigen Receptor T cell-therapy: Clinical Features and outcomes (ACTRIMS Forum 2026) - "Clinical and imaging features, treatment, and outcomes are described. Eleven patients were identified (64% male, median age 70 years, range 57-76), all treated with ciltacabtagene autoleucel, a BCMA-directed CAR-T for multiple myeloma...Partial improvement (2); treated with cyclophosphamide (1), carbidopa-levodopa (2)... CNPs and MNTs following BCMA CAR-T are clinically significant. Initiation of corticosteroids, with adjunctive cyclophosphamide in MNTs may improve neurologic recovery."

CAR T-Cell Therapy • Clinical • Alzheimer's Disease • Cognitive Disorders • Hematological Malignancies • Movement Disorders • Multiple Myeloma

Efficacy and side-effect profile of foslevodopa-foscarbidopa subcutaneous infusion in patients with advanced Parkinson's disease: An ambispective longitudinal study. (PubMed, Can J Neurol Sci) - No abstract available

Adverse events • Journal • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Persistent Tremor in Bipolar Disorder: A Case Report of Idiopathic Parkinson's Disease Superimposed on Lithium and Antipsychotic Effects. (PubMed, Case Rep Psychiatry) - "Management included discontinuing lithium, switching aripiprazole to quetiapine to limit motor worsening, and starting carbidopa-levodopa...When parkinsonian signs are atypical or persist after medication changes, consider idiopathic PD rather than attributing symptoms to side effects. Care is best delivered through close collaboration between psychiatry and neurology to balance dopaminergic therapy with mood stabilization."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Real World Evaluation of Ciltacabtagene Autoleucel (cilta-cel) Toxicity Management: A Single Center Experience (TCT-ASTCT-CIBMTR 2026) - "Seven patients required no interventions for their CRS; 10 received tocilizumab, 7 received dexamethasone...A month later, the patient presented with return of gait disturbances and masked faces so was given a 4th dose of IT chemotherapy with thiotepa and hydrocortisone, with mild symptom improvement. At last follow-up, the patient had just initiated carbidopa-levodopa... Cilta-cel-related toxicities were manageable with early intervention and tailored supportive care, including delayed neurotoxicity. Further research is essential for optimal monitoring and treatment strategies for MNTs and CNPs to improve long-term safety and patient outcomes. 1."

Adverse events • Clinical • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Inflammation • Movement Disorders • Multiple Myeloma • Septic Shock

Dopaminergic Dysfunction in Late-Life Depression (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Mood Disorders • Psychiatry

ProParkB: A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: AbbVie

New trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Autoimmunity to Collagen XVII (BP180-Ag2) in Pemphigoid Associated With Parkinson's Disease. (PubMed, Case Rep Dermatol Med) - "We present the case of an 84-year-old patient with a 16-year history of Parkinson's disease, treated with rotigotine, levodopa, and carbidopa...Additionally, six Parkinson's serum samples without pemphigoid disease were tested as controls, and only one serum sample was reactive to BP180-Ag2. A critical review of the possible pathogenic mechanisms of this rare association is discussed."

Journal • Bullous Pemphigoid • CNS Disorders • Dermatology • Dermatopathology • Immunology • Movement Disorders • Parkinson's Disease

Analgesic Benefit of Low-Dose Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson's Disease: A Non-Standard Therapeutic Application. (PubMed, Mov Disord Clin Pract) - No abstract available

Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease. (PubMed, Mov Disord Clin Pract) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

CARBIDOH: Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Julien Bally | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Hypotension • Movement Disorders • Multiple System Atrophy • Parkinson's Disease

Neuropsychiatric and cognitive safety of subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: insights from a real-world cohort. (PubMed, J Mov Disord) - "Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) represents a transformative therapy for advanced Parkinson's disease (aPD), but real-world neuropsychiatric safety data remain limited, particularly in populations typically excluded from trials. COMT-I emerged as a modifiable risk factor. Findings support broader CSFLI use with structured neuropsychiatric monitoring and proactive clozapine in selected patients."

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • COMT

Response to bilateral globus pallidus interna (GPi) deep brain stimulation in a woman with dystonia due to ATP1A3 p.Arg756Cys (ACMG 2026) - "Treatment and Management After earlier treatment with botulinum toxin and baclofen and unsuccessful trials of carbidopa-levodopa, the patient underwent bilateral GPi DBS placement at age 17...She remains on clonazepam, which has shown efficacy for her dystonia...Her epilepsy is responsive to levetiracetam monotherapy...Diagnostic Workup In childhood, she underwent extensive genetic and metabolic workup for neurodegenerative diseases, including muscle biopsy and CSF studies. ATP1A3 was tested in a research lab with negative results before ATP1A3 p.Arg756Cys was found via gene panel at age 28."

Clinical • Ataxia • CNS Disorders • Depression • Dystonia • Epilepsy • Infectious Disease • Movement Disorders • Parkinson's Disease • Postpartum Depression

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease. (PubMed, Mov Disord Clin Pract) - "LDp/CDp is a new treatment option for advanced PD (aPD). Treatment success depends on education, selecting appropriate patients, setting patient expectations, implementing individualized dosing strategies, and managing adverse effects."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Parkinsonism Exacerbation due to Acute Dopamine Depletion: A Conundrum Revisited. (PubMed, Mov Disord Clin Pract) - "Acute parkinsonism dopamine depletion syndrome (APDDS) might be a more encompassing term to describe to an acute exacerbation of preexisting parkinsonism resulting from recent reduction in dopaminergic or other Parkinson's therapy (eg, DBS failure), or exposure to antidopaminergics. Symptoms include increased rigidity, encephalopathy, hyperthermia, or autonomic instability. Sepsis is a frequent confounder and may be associated with concurrent reduction or discontinuation of carbidopa-levodopa."

Journal • Review • CNS Disorders • Critical care • Infectious Disease • Movement Disorders • Parkinson's Disease • Septic Shock

ONIROS: A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa (clinicaltrials.gov) - P=N/A | N=103 | Recruiting | Sponsor: AbbVie | Trial completion date: Mar 2026 ➔ Jan 2027 | Trial primary completion date: Mar 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder

Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa-Foscarbidopa. (PubMed, Mov Disord Clin Pract) - "CSFLI may exacerbate ICDs in susceptible individuals. Pre-treatment screening and close monitoring are recommended."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Improvement of Pisa syndrome in Parkinson's disease following continuous subcutaneous infusion of foslevodopa/foscarbidopa. (PubMed, Neurol Sci) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

A PRELIMINARY REPORT ON ACCESSIBILITY, AFFORDABILITY, AND AVAILABILITY OF MEDICINES FOR PARKINSON (ADPD 2026) - "The most available medicines were for autonomic symptoms such as omeprazole (98.28%), sildenafil (89.7%), bisacodyl (84.5%), tadalafil (60.3%), and for psychiatric symptoms such as haloperidol (50%) and fluoxetine (48.3%). Among dopaminergic medicines, carbidopa/levodopa was always available in 19% of pharmacies, dopamine agonists in 13.8% (bromocriptine), 6.9% (cabergoline), and 1.7% (ropinirole), and monoamine oxidase B inhibitors in 1.72%...Affordable medicines were those always available in the reference public hospital pharmacy, such as the antipsychotics haloperidol and risperidone, the anticholinergic trihexyphenidyl, and the antidepressant fluoxetine... Similar to other low-income countries, there is poor access to PD medicines in Malawi`s pharmacies due to regulatory, supply chain, and financial barriers."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

PARKINSONISM FOLLOWING VARICELLA-ZOSTER VIRUS (SHINGLES) INFECTION: A CASE REPORT (ADPD 2026) - "She received two courses of oral valacyclovir after recurrence but never IV acyclovir...Sinemet improved most symptoms except foot dystonia... The relationship between parkinsonism and VZV is uncertain, with evidence suggesting but not confirming an association. A veteran cohort study found no increased Parkinson's disease risk after VZV exposure, whereas a metaanalysis and systematic review reported a significant association (1,3). Another study linked higher anti-VZV antibody levels with Parkinson's risk (6)."

Case report • Clinical • CNS Disorders • Dystonia • Gastrointestinal Disorder • Herpes Zoster • Infectious Disease • Movement Disorders • Parkinson's Disease • Varicella Zoster

AADC ENZYME ACTIVITY AND PROTEIN LEVELS IN SERUM DO NOT DIFFERENTIATE DEMENTIA WITH LEWY BODIES FROM CONTROLS OR OTHER DEMENTIAS (ADPD 2026) - "Data for a limited number (n=7) of patients on dopamine-related medication showed a clear increase in AADC enzyme activity and protein levels during levodopa/carbidopa treatment, and a decrease in patients who received risperidone, a combined serotonin 5-HT2A and dopamine D2-receptor antagonist. Serum AADC enzyme activity showed a moderate-strong correlation with serum AADC protein levels. However, neither serum AADC enzyme activity nor AADC protein levels were suitable as biomarkers to detect DLB or to discriminate DLB from other types of dementia. Finally, dopaminergic medication had strong effects on serum AADC enzyme activity and protein levels in the small subset of patients using this medication."

Alzheimer's Disease • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Lewy Body Disease • DRD2

CONTINUOUS SUBCUTANEOUS INFUSION OF FOSLEVADOPA/FOSCARBIDOPA) FOR PEOPLE WITH ADVANCED PARKINSON (ADPD 2026) - "Aims: Continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa a novel treatment of severe motor fluctuations in advanced Parkinson's disease(1). We demonstrate the initial "real world" experience with a novel CSCI for PD in a single center in Ireland. Dosing rates differ in the majority from the initial calculated dose. Common reasons for discontinuation are skin site reactions and neuropsychatric side effects."

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

ATYPICAL PSYCHOSIS IN PARKINSON DISEASE: A RETROSPECTIVE STUDY ON 24-HOUR CONTINUOUS SUBCUTANEOUS INFUSION OF FOSLEVODOPA/FOSCARBIDOPA (ADPD 2026) - "CSCI-induced psychosis is distinct from visual hallucinations observed in typical PD psychosis and likely involves impulsive-compulsive behaviors associated with dopamine dysregulation. While QUIP-CS is seldom used clinically, PDQ39_sub5 provides a practical alternative for assessing psychosis risk, potentially effective for predicting and managing atypical psychosis in PD patients receiving advanced dopaminergic therapies."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

EARLY REAL-WORLD EXPERIENCE OF FOSLEVODOPA/FOSCARBIDOPA INFUSION THERAPY IN PARKINSON'S DISEASE – A SINGLE CENTER RETROSPECTIVE STUDY (ADPD 2026) - "Real-world data from treatment with pLD/pCD infusion at a tertiary centre mirror the results from previous phase III and preliminary reports from an ongoing phase IV study, indicating that the treatment is efficacious and tolerable in most patients. Frail patients who would not have been included in the clinical trials were more likely to terminate treatment. Dropouts due to adverse events call for better identification of risk factors and mitigation strategies."

Real-world • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

INDEX STUDY OF COGNITIVE IMPAIRMENT AMONG MILD PARKINSON'S PATIENTS IN THE MOST POPULOUS STATE IN NIGERIA-KANO (ADPD 2026) - " On bivariate analysis, level of education (p-value 0.031), presence of hypertension (p-value 0.005), higher pulse rate (p-value 0.011), tremor-dominant PD phenotype (p-value 0.032), and levodopa/carbidopa use (p-value 0.048) were found to be significant factors associated with CI in PwPD... PD MCI is common with a prevalence of 25% in Norther Nigeria. Significant variables associated with PD MCI include HTN and lower socio-economic status and lower level of formal education on both bivariate and regression analysis."

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Hypertension • Movement Disorders • Parkinson's Disease